|
業務類別
|
Biotechnology |
|
業務概覽
|
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics. |
| 公司地址
| 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801 |
| 電話號碼
| +1 302 295-3800 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inhibikase.com |
| 員工數量
| 35 |
| Dr. Christopher Cabell, F.A.C.C.,M.D.,M.H.S. |
President and Head, Research and Development |
美元 429.17K |
30/04/2026 |
| Mr. David McIntyre, C.P.A.,L.L.B.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 347.22K |
30/04/2026 |
| Mr. Mark T. Iwicki |
Director and Chief Executive Officer |
美元 624.21K |
30/04/2026 |
|
|
| Mr. Dennis N. Berman |
Independent Director |
30/04/2026 |
| Mr. Arvind Kush |
Independent Director |
30/04/2026 |
| Dr. David Canner, PhD |
Independent Director |
30/04/2026 |
| Mr. Amit D. Munshi |
Chairman of the Board |
30/04/2026 |
| Mr. Roberto Bellini |
Independent Director |
30/04/2026 |
| Mr. Vincent E. Aurentz |
Independent Director |
30/04/2026 |
| Mr. Mark T. Iwicki |
Director and Chief Executive Officer |
30/04/2026 |
|
|
|
|
